Literature DB >> 30602595

Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus.

Lisa Bodei1, Ken Herrmann2,3, Richard P Baum4, Mark Kidd5, Anna Malczewska6, Irvin M Modlin7.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30602595     DOI： 10.2967/jnumed.118.219386

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  4 in total

1.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Authors:  Rudolf A Werner; Thorsten Derlin; Steven P Rowe; Lena Bundschuh; Gabriel T Sheikh; Martin G Pomper; Sebastian Schulz; Takahiro Higuchi; Andreas K Buck; Frank M Bengel; Ralph A Bundschuh; Constantin Lapa
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

2.  PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

Authors:  Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Anna Malczewska; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-14       Impact factor: 9.236

3.  First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.

Authors:  Richard P Baum; Jingjing Zhang; Christiane Schuchardt; Dirk Müller; Helmut Mäcke
Journal:  J Nucl Med       Date:  2021-03-05       Impact factor: 11.082

Review 4.  18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Authors:  Rudolf A Werner; Thorsten Derlin; Constantin Lapa; Sara Sheikbahaei; Takahiro Higuchi; Frederik L Giesel; Spencer Behr; Alexander Drzezga; Hiroyuki Kimura; Andreas K Buck; Frank M Bengel; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.